Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Fludarabine + KTE-X19|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|KTE-X19||KTE-X19 are autologous T-cells engineered to express an anti CD-19 chimeric antigen receptor, which may potentially target CD-19 expressing tumor cells (Blood (2019) 134 (Supplement_1): 754).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||mantle cell lymphoma||not applicable||Cyclophosphamide + Fludarabine + KTE-X19||Phase II||Actionable||In a Phase II (ZUMA-2) trial, conditioning chemotherapy including Cytoxan (cyclophosphamide) and Flurdara (fludarabine) followed by a single infusion of KTE-X19 resulted in an objective response rate of 86% (24/28, 16 complete response, 8 partial response) in patients with relapsed/refractory mantle cell lymphoma (Blood (2019) 134 (Supplement_1): 754).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04162756||Expanded access||Cyclophosphamide + Fludarabine + KTE-X19||Study of KTE-X19 for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18)||Available|